Literature DB >> 10955199

A comparative evaluation of tretinoin gel microsphere, 0.1%, versus tretinoin cream, 0.025%, in reducing facial shine.

J Nyirady1, M Nighland, G Payonk, J Pote, S Phillips, R Grossman.   

Abstract

Tretinoin gel microsphere, 0.1%, is a highly effective anti-acne medication formulated with sponge-like microspheres encapsulating the active ingredient, tretinoin. In addition to minimizing cutaneous irritation, this system may also reduce facial shine. This single-center, double-blind, half-face study evaluated the potential of tretinoin gel microsphere, 0.1%, to reduce the appearance of facial shine compared to tretinoin cream, 0.025%. Thirty-five subjects (ages 12 to 24 years) with moderate acne vulgaris and moderate facial oiliness, were evaluated after 4 consecutive days of product use. On sides treated with tretinoin gel microsphere, 0.1%, investigators found significantly reduced facial shine at 3 and 6 hours posttreatment. Subjects' self-evaluations revealed a significant reduction in facial shine at 3 hours posttreatment. Photographic analyses showed reductions in facial shine for both treatments, but decreases were greater on tretinoin gel microsphere, 0.1%-treated sides. Both therapies were well tolerated, and no adverse events occurred. Tretinoin gel microsphere, 0.1%, has the added benefit of reducing the appearance of facial shine, which is a frequent concern in acne patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955199

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Benzoyl Peroxide Microsphere Formulations: What is the Science Supporting Microsphere Vehicle Technology and Clinical Use?

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2009-09

2.  Microsphere technology: hype or help?

Authors:  Leon H Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2011-05

Review 3.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.